Zynex, Inc. (OTCMKTS:ZYXI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 and Item 9.01 of the Current Report on Form 8-K filed
on May 19, 2017
| Item 2.02 |
Results of Operations and Financial Conditions |
On May 15, 2017, Zynex, Inc. issued a press release reporting its
results of operations for the three months ended March 31, 2017.
A copy of the amended press release is furnished as Exhibit 99.1
to this report.
| Item 9.01 | Financial Statements and Exhibits |
(d)Exhibits
| Exhibits No. | Description | |
| Ex-99.1 | Amendment to the Press Release dated May 15, 2017 |
About Zynex, Inc. (OTCMKTS:ZYXI)
Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications. Zynex, Inc. (OTCMKTS:ZYXI) Recent Trading Information
Zynex, Inc. (OTCMKTS:ZYXI) closed its last trading session up +0.074 at 0.424 with 9,023 shares trading hands.
